Clinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes　- Real-World Evidence From the Kyoto PCSK9 Registry.

Authors

Hideo Tsubata, Naohiko Nakanishi, Noriyuki Wakana, Arito Yukawa, Norimasa Taniguchi, Hirokazu Yokoi, Kiyonari Matsuo, Natsuya Keira, Takashi Okada, Keizo Furukawa, Masahiro Koide, Satoaki Matoba, Kyoto PCSK9 Registry

Published in

Circulation journal : official journal of the Japanese Circulation Society. Jul 11, 2026. Epub Jul 11, 2026.

Abstract

The clinical consequences of discontinuing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have not been elucidated.
We analyzed 208 patients with coronary artery disease treated with PCSK9 inhibitors. During a median follow-up of 1,096 days, 94 patients discontinued treatment and they had a higher incidence of major adverse cardiovascular events (MACE) than those who continued. Event curves diverged approximately 3 years after discontinuation. Multivariable Cox analysis showed that discontinuation was associated with a higher incidence of MACE.
Discontinuation of PCSK9 inhibitors was associated with worse cardiovascular outcomes.

PMID:
42438016
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.